ANTX
Price:
$1.065
Market Cap:
$29.18M
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Industry
Biotechnology
IPO Date
2022-03-25
Stock Exchange
NASDAQ
Ticker
ANTX
According to AN2 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 31.96. This represents a change of 117.34% compared to the average of 14.70 of the last 4 quarters.
The mean historical Current Ratio of AN2 Therapeutics, Inc. over the last ten years is 14.41. The current 31.96 Current Ratio has changed 22.07% with respect to the historical average. Over the past ten years (40 quarters), ANTX's Current Ratio was at its highest in in the June 2025 quarter at 31.96. The Current Ratio was at its lowest in in the March 2021 quarter at 0.
Average
14.41
Median
11.07
Minimum
2.90
Maximum
35.85
Discovering the peaks and valleys of AN2 Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 510.07%
Maximum Annual Current Ratio = 35.85
Minimum Annual Increase = -91.90%
Minimum Annual Current Ratio = 2.90
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 8.43 | 7.07% |
| 2023 | 7.87 | -42.66% |
| 2022 | 13.72 | -22.48% |
| 2021 | 17.70 | 510.07% |
| 2020 | 2.90 | -91.90% |
The current Current Ratio of AN2 Therapeutics, Inc. (ANTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
10.01
5-year avg
10.13
10-year avg
14.41
AN2 Therapeutics, Inc.’s Current Ratio is greater than Q32 Bio Inc. (4.57), greater than Plus Therapeutics, Inc. (1.29), greater than Pluri Inc. (4.81), greater than Boundless Bio, Inc. (14.08), greater than NextCure, Inc. (3.71), greater than iBio, Inc. (8.39), greater than Iterum Therapeutics plc (2.13), greater than SAB Biotherapeutics, Inc. (10.50), greater than Intensity Therapeutics, Inc. (3.60), greater than Verrica Pharmaceuticals Inc. (1.25),
| Company | Current Ratio | Market cap |
|---|---|---|
| 4.57 | $44.54M | |
| 1.29 | $39.62M | |
| 4.81 | $23.49M | |
| 14.08 | $24.62M | |
| 3.71 | $34.11M | |
| 8.39 | $21.16M | |
| 2.13 | $21.14M | |
| 10.50 | $36.32M | |
| 3.60 | $21.70M | |
| 1.25 | $79.91M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AN2 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like AN2 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is AN2 Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for AN2 Therapeutics, Inc. (ANTX)?
What is the highest Current Ratio for AN2 Therapeutics, Inc. (ANTX)?
What is the 3-year average Current Ratio for AN2 Therapeutics, Inc. (ANTX)?
What is the 5-year average Current Ratio for AN2 Therapeutics, Inc. (ANTX)?
How does the current Current Ratio for AN2 Therapeutics, Inc. (ANTX) compare to its historical average?